Paysign Q3 2026 Earnings Report Highlights Growth

Paysign's patient affordability programs drove 42.6% revenue growth and 204.1% net income increase in Q3 2026.

16 cards · 1m 40s · tap to begin

From · · · 1m 40s

Paysign Q3 2026 Earnings Report Highlights Growth

Paysign's patient affordability programs drove 42.6% revenue growth and 204.1% net income increase in Q3 2026.

In brief

Paysign's patient affordability programs drove 42.6% revenue growth and 204.1% net income increase in Q3 2026. Paysign reported $30.8 million revenue, 204.1% year-over-year net income growth, and 64.7% gross margins driven by patient affordability programs. Originally reported by The Motley Fool.

Q3 2026 Revenue

Paysign (PAYS) Q3 2026 Earnings Call Transcript

Revenue grew 42.6% year over year to $30.8 million.

Pharma Revenue Growth

Pharma revenue increased 109.8% year over year to $16.6 million.

Plasma Revenue

Plasma revenue grew 7.5% year over year to $13.8 million.

Gross Margin Expansion

Gross margin expanded 840 basis points to 64.7% year over year.

Net Income Growth

Net income grew 204.1% year over year to $6.7 million.

Patient Affordability Programs

167 active patient affordability programs with 19 new launches in Q3.

Average Program Revenue

Average quarterly revenue per pharma program increased to $99,524.

Patient Financial Assistance

Delivered $367 million in patient financial assistance in Q3.

Dynamic Business Rules Savings

Saved $82.5 million in client costs through dynamic business rules.

Plasma Center Count

562 plasma centers at quarter-end, down from 595 centers last year.

Average Plasma Revenue

Average monthly revenue per plasma center increased to $8,187.

Operating Margin

Operating margin expanded to 23.8% from 7.3% last year.

Plasma Transition Impact

113 plasma centers expected to transition to another provider in Q4.

2026 Revenue Guidance

Revenue guidance of $114 million to $117 million for 2026.

2026 Net Income Guidance

Net income guidance of $23 million to $24 million for 2026.

2026 Adjusted EBITDA Guidance

Adjusted EBITDA guidance of $38.5 million to $40.0 million for 2026.

The main idea

Paysign reported $30.8 million revenue, 204.1% year-over-year net income growth, and 64.7% gross margins driven by patient affordability programs.

Read the original on The Motley Fool

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on paysign and related topics.